Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints.
Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints.
复制标题
神经性厌食症的体重增加不会改善粪便菌群，分支链脂肪酸剖面和胃肠道抱怨。
DOI：
10.1038/srep26752
复制
发表时间：
2016-05-27
影响因子：
4.6
通讯作者：
Penders J
中科院分区：
文献类型：
--
作者：
Mack I;Cuntz U;Grämer C;Niedermaier S;Pohl C;Schwiertz A;Zimmermann K;Zipfel S;Enck P;Penders J
肠道菌群不仅影响宿主代谢，还可以通过微生物-肠-脑轴影响大脑功能和行为。为了探索肠道微生物群在神经性厌食症（AN）中的潜在作用，我们全面调查了这些患者在体重增加前（n = 55）和体重增加后（n = 44）的粪便微生物群和短链脂肪酸，并与正常体重的参与者（NW, n = 55）进行了比较，以及饮食摄入和胃肠道不适。我们发现，与NW参与者相比，AN患者的微生物受到了严重的干扰，黏液降解物和梭状芽孢杆菌I、XI和XVIII集群成员的水平更高，产生丁酸盐的Roseburia spp的水平降低。作为蛋白质发酵标志的支链脂肪酸浓度升高。在个体限制性和暴食/净化型an亚型中观察到微生物群落组成的明显扰动。体重增加后，微生物丰富度增加，但肠道菌群和短链脂肪酸谱的紊乱以及一些胃肠道症状没有恢复。这些见解为调节肠道微生物群以改善标准治疗的结果提供了新的线索。
The gut microbiota not only influences host metabolism but can also affect brain function and behaviour through the microbiota-gut-brain axis. To explore the potential role of the intestinal microbiota in anorexia nervosa (AN), we comprehensively investigated the faecal microbiota and short-chain fatty acids in these patients before (n = 55) and after weight gain (n = 44) in comparison to normal-weight participants (NW, n = 55) along with dietary intake and gastrointestinal complaints. We show profound microbial perturbations in AN patients as compared to NW participants, with higher levels of mucin-degraders and members of Clostridium clusters I, XI and XVIII and reduced levels of the butyrate-producing Roseburia spp. Branched-chain fatty acid concentrations, being markers for protein fermentation, were elevated. Distinct perturbations in microbial community compositions were observed for individual restrictive and binge/purging AN-subtypes. Upon weight gain, microbial richness increased, however perturbations in intestinal microbiota and short chain fatty acid profiles in addition to several gastrointestinal symptoms did not recover. These insights provide new leads to modulate the intestinal microbiota in order to improve the outcomes of the standard therapy.